Terms: = Sarcomas AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
12 results:
1. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
2. The mutational repertoire of uterine sarcomas and carcinosarcomas in a Brazilian cohort: A preliminary study.
da Costa LT; Dos Anjos LG; Kagohara LT; Torrezan GT; De Paula CAA; Baracat EC; Carraro DM; Carvalho KC
Clinics (Sao Paulo); 2021; 76():e2324. PubMed ID: 33503190
[TBL] [Abstract] [Full Text] [Related]
3. her4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.
Li X; Huang Q; Wang S; Huang Z; Yu F; Lin J
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):345-362. PubMed ID: 32181480
[TBL] [Abstract] [Full Text] [Related]
4. Molecular profiling of the biphasic components of hepatic carcinosarcoma by the use of targeted next-generation sequencing.
Zhang X; Bai Q; Xu Y; Wang W; Chen L; Han J; Zhu H; Zhang Z; Hou Y; Zhou J; Zhou Y; Ji Y
Histopathology; 2019 May; 74(6):944-958. PubMed ID: 30629754
[TBL] [Abstract] [Full Text] [Related]
5. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract] [Full Text] [Related]
6. Targetable Alterations in Adult Patients With Soft-Tissue sarcomas: Insights for Personalized Therapy.
Lucchesi C; Khalifa E; Laizet Y; Soubeyran I; Mathoulin-Pelissier S; Chomienne C; Italiano A
JAMA Oncol; 2018 Oct; 4(10):1398-1404. PubMed ID: 29801054
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer.
Cavalieri S; Perrone F; Miceli R; Ascierto PA; Locati LD; Bergamini C; Granata R; Alfieri S; Resteghini C; Galbiati D; Busico A; Paielli N; Patuzzo R; Maurichi A; Gallino G; Ruggeri R; Mariani L; Palla M; Licitra L; Bossi P
Eur J Cancer; 2018 Jul; 97():7-15. PubMed ID: 29734047
[TBL] [Abstract] [Full Text] [Related]
8. her4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.
Wang H; Sun W; Sun M; Fu Z; Zhou C; Wang C; Zuo D; Zhou Z; Wang G; Zhang T; Xu J; Chen J; Wang Z; Yin F; Duan Z; Hornicek FJ; Cai Z; Hua Y
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1839-1849. PubMed ID: 29524631
[TBL] [Abstract] [Full Text] [Related]
9. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V; Groisberg R; Hess K; Fu S; Wheler J; Hong DS; Janku F; Zinner R; Piha-Paul SA; Ravi V; Benjamin RS; Patel S; Somaiah N; Herzog CE; Karp DD; Roszik J; Meric-Bernstam F; Subbiah V
Sci Rep; 2017 Nov; 7(1):15963. PubMed ID: 29162825
[TBL] [Abstract] [Full Text] [Related]
10. The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer.
Kwak E
Oncologist; 2011; 16(11):1498-507. PubMed ID: 22016476
[TBL] [Abstract] [Full Text] [Related]
11. Activation of the neuregulin-1/ErbB signaling pathway promotes the proliferation of neoplastic Schwann cells in human malignant peripheral nerve sheath tumors.
Stonecypher MS; Byer SJ; Grizzle WE; Carroll SL
Oncogene; 2005 Aug; 24(36):5589-605. PubMed ID: 15897877
[TBL] [Abstract] [Full Text] [Related]
12. Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells.
Ricci C; Landuzzi L; Rossi I; De Giovanni C; Nicoletti G; Astolfi A; Pupa S; Menard S; Scotlandi K; Nanni P; Lollini PL
Int J Cancer; 2000 Jul; 87(1):29-36. PubMed ID: 10861449
[TBL] [Abstract] [Full Text] [Related]
